Why Shares of Solid Biosciences Are Jumping Today
Shares of Solid Biosciences (NASDAQ: SLDB) are up 24% as of 11:15 a.m. EDT as the company prepares to present long-term data for three patients in a phase 1/2 study of its treatment for Duchenne muscular dystrophy. The presentation will take place at the World Muscle Society Virtual Congress.
Image source: Getty Images.
Solid's drug candidate -- SGT-001 -- is a gene transfer therapy designed to address the absence of the dystrophin protein in those with the disease. Early data suggests SGT-001 could slow or stop the progression of Duchenne muscular dystrophy regardless of how far the disease has progressed.
Source Fool.com
